Rossi Alfredo, Caro Gemma, Magri Francesca, Fortuna Maria Caterina, Carlesimo Marta
Department of Clinical Internal Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Explor Target Antitumor Ther. 2021;2(5):490-495. doi: 10.37349/etat.2021.00059. Epub 2021 Oct 31.
Adjuvant hormonal therapy is one of the most important treatments of hormone-receptor-positive breast cancer and includes selective estrogen receptor modulators, aromatase inhibitors, and luteinizing hormone-releasing hormone analogs. In patients receiving these drugs, a progressive recession of frontal-temporal hairlines is often observed, such as a certain grade of hair miniaturization in the same areas and the central scalp area, producing a pseudo-female androgenic alopecia, which has to be considered oncotherapy-induced alopecia. The aim of this work, is to describe the clinical aspects and pathogenesis of this type of alopecia and to analyze the different drugs which have been proposed until now. The authors concude that topical hormones should not be considered as a therapeutic approach because of their direct or indirect oncogenic potential. A therapeutic approach that could be both safe and effective is proposed.
辅助激素治疗是激素受体阳性乳腺癌最重要的治疗方法之一，包括选择性雌激素受体调节剂、芳香化酶抑制剂和促性腺激素释放激素类似物。在接受这些药物治疗的患者中，常观察到额颞发际线逐渐后移，如同一区域和头皮中部出现一定程度的毛发变小，产生假性女性雄激素性脱发，这必须被视为肿瘤治疗引起的脱发。这项工作的目的是描述这种脱发类型的临床特征和发病机制，并分析目前已提出的不同药物。作者得出结论，由于局部激素具有直接或间接的致癌潜力，不应将其视为一种治疗方法。提出了一种既安全又有效的治疗方法。
